Anavex life sciences announces participation at 5th pharma pricing, reimbursement & market access 2021

New york, sept. 27, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that its president and chief executive officer, christopher u. missling, phd, will join a panel discussion titled, “fragile x syndrome case study: from preclinical to clinical, making drug development efficient through community-based collaboration” at the 5th pharma pricing, reimbursement & market access 2021 conference on wednesday, september 29th at 2:40 pm et.
AVXL Ratings Summary
AVXL Quant Ranking